中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(6)：349-352,4.DOI:10.1007/s10330-009-0063-1
FA方案用于急性髓系白血病不同治疗阶段疗效分析
Analyses of therapeutic effects using rludarabine and cytarabine on acute myeloid leukemia at different stages during treatment
摘要
Abstract
Objective:To evaluate the therapeutic effect of the fludarabine and cytarabine (FA) regimen on acute myeloid leu-kemia (AML) at different phases during treatment. Methods: A total of 185 patients with AM L were divided into 4 groups based on the outcome of previous treatments. Patients in Group 1 had no remission after the first course of induction chemotherapy (n = 55). Patients in Group 2 had no remission after no less than two courses of induction chemotherapy (n = 41). Patients in Group 3 had early relapse (n = 40). Patients in Group 4 had late relapse (n = 49). Patients in groups 2, 3 and 4 had refractory AML or AML with relapse. We assessed the efficacy and toxicity of FA combination chemotherapy in each of these 4 groups. Results: The complete remission (CR) rates of Groups 1, 2, 3 and 4 were 74.5% (41/55), 45.9% (19/41), 17.5% (7/40) and 38.8% (19/49), respectively. The CR rate was higher in Group 1 than in the other 3 groups (34.6%, 45/130) (P = 0.000). A sig-nificant correlation was found between CR rate and the number of chemotherapeutic courses (P = 0.023). The main adverse reactions included bone marrow suppression and secondary infection. Conclusion: FA regimen is a good choice for patients with AML, especially those who have failed to achieve CR after the first course of induction chemotherapy.关键词
acute myeloid leukemia (AML)/fludarabine/cytarabineKey words
acute myeloid leukemia (AML)/fludarabine/cytarabine分类
医药卫生引用本文复制引用
Na Xu,Xiaoli Liu,Qingfeng Du,Lingyun Ouyang,Zhi Liu,Lijun Hou..FA方案用于急性髓系白血病不同治疗阶段疗效分析[J].中德临床肿瘤学杂志（英文版）,2009,8(6):349-352,4.基金项目
Supported by a grant from the Planned Science and Technology Project of Guangzhou (No. 2006Z3-E0401). （No. 2006Z3-E0401）
